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Abstract
OBJECTIVE: To examine the clinical effects of a mix-
ture of Chinese Yam and Epimedium in patients
with stable moderate or severe chronic obstructive
pulmonary disease (COPD).
METHODS: Forty-nine patients with COPD were
randomly allocated to a group whose usual treat-
ment was supplemented with oral Chinese
Yam-Epimedium mixture, or a control group given
placebo. For each patient, body mass index, airflow
obstruction, dyspnea, and exercise capacity were
measured and converted into the BODE index be-
fore treatment and at one and three months after
initiation of treatment. Participants also completed
the St George's Respiratory Questionnaire (SGRQ)
at the same intervals.
RESULTS: After one month, improvements were
seen in the BODE index and SGRQ of participants
taking Chinese Yam-Epimedium mixture compared
to controls. There were statistically significant differ-
ences in the SGRQ: three of its components and the
total SGRQ scores were significantly decreased (P<
0.05), respiratory symptom scores had improved
(P<0.01), and the dyspnea component of the BODE
index had significantly decreased (P<0.05). Similar
improvements were observed after three months
of treatment, but exercise tolerance had also im-
proved: the six-minute walking distance had signifi-
cantly increased (P<0.05) in the treatment group
when compared with controls.
CONCLUSION: Chinese Yam-Epimedium mixture
can significantly improve dyspnea, exercise capaci-
ty, and the quality of life of patients with stable
moderate or severe COPD.
© 2012 JTCM. All rights reserved.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a
chronic progressive respiratory disorder, which causes
substantial disability. As well as difficulty breathing, pa-
tients report that their quality of life is reduced by oth-
er symptoms that include cough, poor exercise toler-
ance, anxiety, and low mood[1]. Patients with COPD
benefit from pulmonary rehabilitation to address dis-
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ease progression, control symptoms and improve quali-
ty of life. In the 1970s, Chinese Yam-Epimedium mix-
ture was used to good effect in the treatment of chron-
ic bronchitis and emphysema, but no paper was pub-
lished to report it because of the irregular academic sit-
uation at the time. More recently, this observation has
been reinforced by studies that have shown that the
mixture improves diaphragmatic contractility in ani-
mal models of COPD[2]. We conducted a pilot single
blind, randomized, placebo controlled trial of oral Chi-
nese Yam-Epimedium mixture in patients with stable
moderate or severe COPD. The therapeutic effects
were evaluated by the BODE index (body mass index,
airflow obstruction, dyspnea, and exercise capacity)
and the St. George's Respiratory Questionnaire
(SGRQ).
MATERIALS ANDMETHODS
Recruitment of participants
Participants meeting the diagnostic criteria for moder-
ate or severe COPD[3] were recruited from the outpa-
tient department and wards of our institution between
March 2009 and June 2011. We excluded patients who
had coexisting cardiac, neurological, hepatic or renal
disease, those with tumors, those with other respiratory
diseases that did not meet the diagnostic criteria for
COPD, and those who declined to participate. All par-
ticipants gave informed consent in accordance with
Good Clinical Practice regulations formulated by the
State Food and Drug Administration of the People's
Republic of China[4]. Participants were randomized in-
to treatment or placebo groups.
Preparation of Chinese herbal drugs
Chinese Yam-Epimedium Mixture was prepared from
30 g ShanYao (Rhizoma Dioscoreae) and 12 g Xian-
LingPi (Herba Epimedii). The drugs were immersed in
water for 30 min, decocted twice, then filtered. The fil-
trate was concentrated into a volume of 160 mL. The
concentrated liquid was sterilized in a glass jar by auto-
claving. Dark brown distilled water mixed with cara-
mel was used as placebo.
Treatment and data collection
Participants continued their usual treatment with West-
ern medicine and pulmonary rehabilitative treatment.
Chinese Yam-Epimedium mixture was administered
orally to patients in the treatment group at a dose of
80 mL twice daily for three months. Those in the place-
bo group received the same volume at the same dosing
frequency. Data was collected by an unblinded investi-
gator. The BODE index was measured and calculated
and SGRQ completed before treatment, and one and
three months after commencing the trial.
Calculation of BODE index[5]
Forced expiratory volume in one second (FEV1) was
measured 30 min after inhalation of 200 mg salbuta-
mol (Lung Function Tester, Erich Jaeger GmbH,
Hesse-Darmstadt, Germany), and the percentage of
the predicted value (FEV1(%)) was calculated. On the
same day, the extent of dyspnea was measured by the
modified Medical Research Council (MMRC) scale[6],
the 6-minute walk distance test (6MWD) was conduct-
ed[7], and body mass index (BMI: weight (kilograms)/
height (metres)2) was calculated. The BODE index
combines FEV1(%), 6MWD, MMRC, and BMI into
a single score, as shown in table 1, and ranges from 0
and 10 points: a lower score indicates better health sta-
tus.
Table 1 Criteria for calculating BODE index
variable
FEV1%
6MWD(m)
MMRC
BMI(kg/m2)
0
≥65
≥350
0-1
>21
points
1
50-64
250-349
2
≤21
2
36-49
150-249
3
3
≤35
≤149
4
The St George's respiratory questionnaire[8]
The questionnaire contains 50 questions divided into
three components: respiratory symptoms (cough, ex-
pectoration and frequency of asthma attacks); activity
limitation (dressing, housework, walking uphill, and
playing sports or games); and impact on psycho-social
function (anxiety, disappointment and distress). The
summed scores for all questions in the first component
comprises the symptoms score, the summed scores of
questions 3 and 7 in the second component comprises
the activity score, and the summed scores for questions
1, 2, 4, 5, 6, 8 and 10 in the second component com-
prises the impact score. The total score was obtained
by adding that of the three components. The score was
calculated by dividing the summed scores of positive re-
sponses by the adjusted maximum possible score for
that component, and then multiplying by 100. The
score varied from 0 to 100, with lower scores indicat-
ing better health status.
Participants were asked to complete the questionnaire
without assistance, although an investigator could clari-
fy individual questions or read questions aloud to par-
ticipants that had difficulty reading.
Statistical analysis
SPSS software (version 13, SPSS IBM, Chicago, USA)
was used for statistical analysis. Data are expressed as
the mean ± standard deviation (SD), and the groups
were compared using the t-test,and uncontinuous vari-
ables are expressed as mean rank and were statistically
analyzed by Mann-Whitney U test.
RESULTS
We recruited 58 participants to the study; their ages
ranged from 58 to 90 years. Forty-nine patients com-
pleted the trial. Of these, 46 were male and 3 female;
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their mean age was 81±3 years. On the basis of their
pulmonary function, 10 cases fulfilled the criteria[3] for
stage II, 23 cases for stage III and 16 cases for stage IV
COPD. Twenty-six participants were randomized to
the treatment group, and 23 to the control group. 9
cases did not complete the trial due to death (2 cases
perished from an incurable lung infection), cerebral in-
farction (1 case), the surgical operation of incarcerated
indirect inguinal hernia (1 case), refusal to come back
to the hospital for a check due to worrying about aggra-
vation of their illness by going out in cold weather (3
cases), and their unwillingness to repeated examination
(2 cases).
Participants'age, lung function, BODE index, and
SGRQ score before treatment are listed in Table 2.
There were no significant differences between the treat-
ment and control groups. None of any adverse event
was reported in both groups.
The changes in BODE index and four variables in
BODE index after treatment are shown in Table 3. Af-
ter one month, MMRC was significantly decreased in
the treatment group compared to controls (P<0.05), a
trend that was also seen at three months (P<0.01). Ex-
ercise tolerance also improved in the treatment group:
after three months 6MWD had increased by 64 meters
from baseline (P<0.05). Also, improvements were seen
in the BODE index, which had significantly decreased
from baseline (P<0.05). Although FEV1% after three
months of treatment was higher than baseline, this dif-
ference was not significantly different.
Table 2 Comparison of patient's age, lung function, BODE index, and SGRQ score between the two groups before treatment ( xˉ ±s)
Group
Treatment
Control
Age
80.1±8.9
80.8±7.3
BODE
6.1±2.4
6.1±3.2
FEV1%
39.7±15.7
38.2±18.1
MMRC
2.9±0.8
2.8±1.0
6MWD(m)
240.0±128.5
220.0±173.3
BMI
20.6±4.8
21.2±4.2
Symptoms
54.1±20.7
53.3±17.6
Activity
57.3±23.5
55.5±29.6
Impacts
55.7±16.3
55.2±19.9
Total score
55.3±17.1
53.5±20.2
Table 3 The changes in BODE index and its four constituent variables after treatment in the two groups ( xˉ ±s)
Treatment duration
1 month
3 months
Group
Treatment
Control
P
Treatment
Control
P
BODE index
4.6±2.7
6.2±3.5
0.094
4.0±2.7
6.4±3.5
0.015
FEV1%
43.0±17.1
38.5±17.8
0.477
42.4±18.5
38.4±17.4
0.495
MMRC
2.0±.10
2.8±1.2
0.021
1.6±1.3
2.8±1.2
0.003
6MWD(m)
287.3±140.0
200.6±172.9
0.085
304.1±149.4
198.6±187.8
0.047
BMI
21.0±4.8
21.3±3.0
0.819
21.2±4.9
21.1±3.9
0.984
The measures of disease severity, physical function and
quality of life recorded in the SGRQ are shown in ta-
ble 4. There were significant improvements in the activ-
ity score, the impacts score, the total score (P<0.05 for
each) and the symptoms score (P<0.01) in the treat-
ment group after one month of treatment, a trend that
continued in the treatment group when compared to
controls after three months (P<0.01).
Table 4 Comparison of changes in SGRQ scores after treatment ( xˉ ±s)
Treatment duration
1 month
3 months
Group
Treatment
Control
P
Treatment
Control
P
Symptoms
32.8±17.3
51.5±16.7
0.001
27.5±14.9
52.8±18.1
0.001
Activity
38.1±24.4
54.4±26.7
0.049
26.2±23.2
54.4±29.1
0.001
Impacts
45.1±18.8
57.0±20.9
0.017
37.0±20.8
57.5±21.3
0.004
Total score
36.7±19.0
54.3±17.4
0.005
32.6±17.0
54.7±19.1
0.001
DISCUSSION
COPD is a long term condition that results in dimin-
ished quality of life, reduced physical functioning, and
has a high social and financial cost for patients, their
families and society as a whole[9,10]. Pulmonary rehabili-
tation is an important aspect of treatment for patients
with stable moderate or severe COPD; it aims to im-
prove quality of life and day-to-day functioning as well
as ameliorating respiratory symptoms. Routine pulmo-
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nary function tests per se do not measure quality of life
of patients with COPD, but recently the BODE index
and SGRQ have been recognized internationally as the
indices that most reliably and reproducibly reflect the
impact of pulmonary rehabilitation[11-14]. The BODE in-
dex combines four variables that combine physiological
disturbance and physical function into a single score:
body mass index (B), airflow obstruction (O), dyspnea
(D), and exercise capacity (E). It incorporates an assess-
ment of symptoms, nutritional state, and exercise ca-
pacity as well as a spirometric measure of airflow
(FEV1%), reflects COPD patients' global health status
and is closely correlated with disease progression[15, 16].
The St George's Respiratory Questionnaire (SGRQ) as-
sesses the extent to which patients' quality of life is di-
minished as a result of lung disease, examining its influ-
ence upon respiratory symptoms, exercise tolerance, ac-
tivities of daily living, and psychological wellbeing.
In this study, participants who had received one month
of treatment with Chinese Yam-Epimedium Mixture
reported significantly reduced respiratory symptoms
compared to those who had taken placebo. Each of the
three components of the SGRQ were significantly low-
er in the treatment cohort (P<0.05), as was the total
score. The extent of respiratory symptoms, which was
evaluated with the scores of the first part of SGRQ,
was significantly lower in the treatment group (P<
0.01), a difference that was still seen after three
months. At three months, improved physical function
was also evident: there was an increase in the mean dis-
tance achieved in the 6MWD of 64 m in the treatment
group compared to controls (P<0.05). Interestingly, al-
though the MMRC component of the BODE index al-
so significantly improved (P<0.05), there was no signif-
icant difference in FEV1% between the groups.
COPD affects the lungs, causing cough, bronchocon-
striction and wheeze, but the resultant hyperexpansion
of the lungs can also affect the lung, spleen and kidney.
In Chinese medicine, it is thought that a deficiency in
the lungs' Qi can trigger COPD. The incidental focus
of COPD lies in the lung, whereas its fundamental
consequences for the whole person are a result of defi-
ciencies of the lung, spleen, and kidney. If the lung is
considered the "child" organ, it "robs" the mother or-
gan – the spleen – and the long diseased "child" or-
gan, e.g., the lung, may render its "mother" organ, e.g.,
the spleen, affected, so as lead to dysfunction of splenic
transportation. In long-standing disease the kidney-Qi
is consumed, causing a failure of the kidney to pro-
mote inspiration, and thereby exercise-induced ast-
hma[17,18]. Having relieved the acute symptoms, princi-
ples of traditional Chinese medicine require the funda-
mental cause to be addressed by invigorating the spleen
and tonifying the kidney[19,20]. Chinese Yam-Epimedi-
um mixture is a well-recognized recipe. The recipe Sh-
anYao (Rhizoma Dioscoreae) is sweet in taste, neutral
in property and acts on the spleen, lung, and kidney
meridians, and can invigorate the spleen, nourish the
lung, and replenish the kidney. XianLingPi (Herba Epi-
medii) is sweet in taste, warm in property and acts on
the liver and kidney meridians, and can warm and toni-
fy the yang of the kidney, and relieve cough and asth-
ma. Modern studies of Chinese herbal drugs have iden-
tified polysaccharide, a major component of ShanYao
(Rhizoma Dioscoreae), as a candidate molecule to ex-
plain its therapeutic benefits. Polysaccharide is an anti-
oxidant that can slow ageing and enhance immunity.
Similarly, total flavones, found in XianLingPi (Herba
Epimedii), are anti-inflammatory, reduce allergic reac-
tions, relieve cough and asthma, eliminate phlegm, en-
hance immunity, reduce blood viscosity, and inhibit
thrombosis[21,22]. Together these two Chinese herbal
drugs would be expected to invigorate the spleen, re-
plenish the kidney, nourish the lung, strengthen im-
mune response, improve general health, relieve cough
and asthma, eliminate phlegm, and play an active role
in the prevention and cure of general inflammation
and microthrombus for patients with COPD. Tradi-
tional Chinese medicine plays a unique role in treat-
ment of and recovery from chronic diseases, an ap-
proach that is simple, effective, cheap and suitable for
long term use.
The results from this trial showed that Chinese
Yam-Epimedium mixture improved respiratory symp-
toms to significantly reduce dyspnea index, to enhance
exercise tolerance, and to diminish the impact of lung
disease on psychosocial functioning so as to improve
the quality of life and the prognosis in the patients
with COPD. The simplicity and low cost of Chinese
herbal drugs makes them particularly suited to the
long term management of chronic diseases such as
COPD, and is worthy of further research.
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